Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Colorectal Cancer: early-phase trial registry
154 of 382 indexed Colorectal Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #14 of 28,963 conditions by registered trial count.
382 US clinical trials · 154 currently recruiting · #14 of 28,963 conditions by registered trial count
Colorectal Cancer: 382 US clinical trials tracked, 154 recruiting.
Colorectal Cancer is the subject of 382 registered US clinical trials on ClinicalTrials.gov, 154 of them currently open to new participants. 12 are in Phase 3-4 (later-stage) and 196 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 22 of these trials.
Open enrollment, early-phase tilt
Colorectal Cancer has 382 registered US clinical trials, 154 of them open to new participants right now, about 40% of the total.
- 154
- recruiting participants now
- 40%
- of trials open to enrollment
- 12
- in Phase 3-4 (later-stage)
- 22
- top sponsor: Memorial Sloan Kettering Cancer Center
Corpus placement: #14 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.
Key findings
What ClinicalTrials.gov does not surface for Colorectal Cancer on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.
-
Colorectal Cancer is recruiting above its size-band peers.
154 of 382 indexed trials (40.3%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Colorectal Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 22 of 382 trials (5.8%). 217 distinct sponsors appear on at least one study for this condition label.
-
Typical Colorectal Cancer enrolment sits around 132 participants.
Median target enrolment is 132 among the 370 trials that report a genuine target (sentinel values excluded). 157 of those (42.4%) plan for fewer than 100 participants.
-
Colorectal Cancer research is mostly interventional.
315 interventional and 67 observational studies make up this index (82.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
382 total, page 3 of 8
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Perspective Therapeutics
NCT06710756
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
AstraZeneca
NCT06973161
Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)
Rgenta Therapeutics
NCT06462183
Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis
Case Comprehensive Cancer Center
NCT07044362
The Florida ASCENT Study
University of Florida
NCT07042243
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
Apollo Therapeutics
NCT06399757
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
Roswell Park Cancer Institute
NCT03965234
Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer
Virginia Commonwealth University
NCT06728072
Ultrasound and Photoacoustic Imaging for Enhanced Differential Diagnosis of Rectal Cancer
Washington University School of Medicine
NCT04339374
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
Kahr Bio Australia Pty
NCT07235293
Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE Trial
Dana-Farber Cancer Institute
NCT06202183
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
Memorial Sloan Kettering Cancer Center
NCT04668872
COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER
Massachusetts General Hospital
NCT05692024
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
Cartography Biosciences
NCT07321106
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Angiex
NCT06440005
Manipulation of the Gut Microbiome by a Standardized Preoperative Diet to Prevent Colorectal Cancer Recurrence and Metastasis Following Surgery
University of Chicago
NCT06349590
A Study to Determine the Effect of CT3001 in Patients with Advanced Solid Tumors
Crossignal Therapeutics
NCT06598007
IDOV-Immune for Advanced Solid Tumors
ViroMissile
NCT06910657
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
Takeda
NCT06562543
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Blue Earth Diagnostics
NCT07432633
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
National Cancer Institute (NCI)
NCT05286814
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
Lumicell
NCT02584244
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Radiopharm Theranostics
NCT07189871
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
BioEclipse Therapeutics
NCT04282044
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)
SCRI Development Innovations
NCT07011576
KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06411691
A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer
University of Chicago
NCT05200442
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
University of California, Irvine
NCT06580002
Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial
Medical College of Wisconsin
NCT07227077
Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
NCT06731998
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
Baylor College of Medicine
NCT03740256
Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06205836
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
Northwestern University
NCT05576896
Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)
M.D. Anderson Cancer Center
NCT06358430
Resistance Exercise and Creatine in Colorectal Cancer
University of South Carolina
NCT06420726
A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome
M.D. Anderson Cancer Center
NCT05411718
Precision-MRD: Prospective Observational Study of Biomarker-directed Systemic Therapy for Colorectal Cancer Patients With Minimal Residual Disease
M.D. Anderson Cancer Center
NCT06878131
The Food Environment, Microbial Cysteine Metabolism, and Cancer Disparities
Purdue University
NCT07086833
Tislelizumab in People With Colorectal Cancer
Memorial Sloan Kettering Cancer Center
NCT06529523
The Impact of PReOPerative Exercise and NutritionaL Optimization on Perioperative Outcomes for Patients Undergoing Treatment for Rectal Cancer: The PROPEL Trial
Dana-Farber Cancer Institute
NCT06565052
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
Hefei TG ImmunoPharma Co.
NCT05746897
Individualized Dose Escalation of 5-FU for Gastrointestinal Cancer
Dartmouth-Hitchcock Medical Center
NCT05780684
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Zumutor Biologics
NCT06451497
A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer
Memorial Sloan Kettering Cancer Center
NCT06130280
GCC19CART for Patients With Metastatic Colorectal Cancer
Lyell Immunopharma
NCT05319314
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
Lantheus Medical Imaging
NCT06298916
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
M.D. Anderson Cancer Center
NCT05343013
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
University of California, Irvine
NCT07447050
Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
Weill Medical College of Cornell University
NCT06300463
Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas
University of California, Irvine
NCT04920032
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 128 |
| Phase 2 | 68 |
| Phase 3 | 9 |
| Phase 4 | 3 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
What is open for Colorectal Cancer right now
154 recruiting of 382 indexed (40% open).
Phase mix: 12 late (III/IV) vs 196 early (I/II) (early-phase heavy).
Top sponsor: Memorial Sloan Kettering Cancer Center (22 trials), 9 others listed. 50 shown below, recruiting first. #14 of 28,963 conditions by registered trial count.
How open-enrollment share is computed
Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.
Frequently Asked Questions
How many clinical trials are there for Colorectal Cancer?
PlainTrial tracks 382 US clinical trials for Colorectal Cancer, of which 154 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Colorectal Cancer?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.